The future is now: SGLT2 inhibitors and type 1 diabetes – What about exercise?https://doi.org/10.1016/j.diabres.2019.107806doi:10.1016/j.diabres.2019.107806Max Lennart EcksteinNils FreitagMoritz SchumannNorbert Joachim TripoltHarald Sourij
SGLT 2 InhibitorsArterial HypertensionDiabetes MellitusSodium-glucose co-transporter-2 (SGLT2) inhibitors are a new class of medications used for the treatment of diabetes mellitus (DM). It has been shown that, in addition to a favorable metabolic effect, they significantly reduce atherosclerotic ...
SGLT-2 Inhibitors: What The Nephrologist Needs To KnowAndrew J. King
SGLT2 inhibitorstype 2 diabetesSodium-glucose cotransporter-2 (SGLT2) inhibitors can decrease risk for heart failure in patients with type 2 diabetes and can decrease risk of major cardiovascular events in patients with heart failure (HF) and diabetes. Specific SGLT2 inhibitors can also decrease ...
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i)Heart failure (HF)Heart failure with preserved ejection fraction (HFpEF)Heart failure with reduced ejection fraction (HFrEF)SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality ...
Sodium-glucose co-transporter type 2 (SGLT-2)-inhibitors represent a newly-introduced anti-diabetic drug class with pleiotropic actions extending above their glucose-lowering efficacy. Herein, we provide an overview of preclinical and clinical-trial evidence supporting a protective effect of SGLT-2 ...
After discovering the role of sodium – glucose transporter 2 (SGLT2) in glucose homeostasis, its inhibition consists a new hypoglycemic mechanism and has become an attractive target for treatment. A plethora of SGLT2 inhibitors has been developed and can be found in various phases of clinical ...
Managing Adverse Events Related to SGLT2 Inhibitors: What a Pharmacist Needs to Know to Optimize Clinical.The article discusses the management of hyperglycemia in patients with type 2 diabetes mellitus (T2DM). Also cited are the considerations in glycemic control targets including duration of disease,...
Objectives: To explore (1) to what extent regulators' opinions regarding the need to communicate safety issues related to sodium-glucose cotransporter-2 (SGLT2) inhibitors might be influenced by their concern about the safety issue, and (2) whether regulators' concerns mi...